Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 181

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 181
---
. The grant-date fair value does not necessarily reflect the value of shares which may be received in the future with respect to these awards. The grant-date fair value of the stock options in this column is a non-cash expense for us that reflects the fair value of the stock options on the grant date and therefore does not affect our cash balance. The fair value of the stock options will likely vary from the actual value the holder receives because the actual value depends on the number of options exercised and the market price of our Common Stock on the date of exercise |

| (2) | Including $57,000 for                                                                                                              
 Bernard’s role as Company’s VP head of strategy. On April 1, 2025, we granted an award under the Company’s ESOP                    
 to Bernard Bartal, the Company’s Chairman, of options for 240,000 shares of Common Stock at a per shares exercise price of         
 $0.30 and exercisable over an eight year period, with such option vesting on a quarterly basis over eight (8) consecutive calendar 
 quarters in equal instalments  of 30,000 options shares on the last day of such quarter, beginning with the quarter ended          
 March 31, 2025, subject to the continued provision of services to the Company by Mr. Bartal.                                       |

| (3) | Mr. Jacobson resigned from the Company’s board of directors effective as of June 30, 2025. |

| (4) | Mr. Flom resigned from the Company’s board of directors effective as of December 1, 2024. |

Under the current Company’s policies, each director is to receive
cash compensation of $10,000 biannually, $1,000 per meeting or $300 for a virtual meeting.

Stock Plan

In March 2021, we adopted the Global Share Incentive
Plan (2021) (the “2021 Plan”), providing for the grant of non-qualified stock options and incentive stock options to purchase
shares of our common stock, restricted and unrestricted share awards and grant of restricted stock units, to the employees, services providers,
directors, officers, consultants and affiliates of the Company and its subsidiaries. The Plan, including the Appendix for Israeli taxpayers
was approved by our stockholders by written consent on March 10, 2021. We initially reserved 5,000,000 shares of our Common Stock issuable
under the 2021 Plan.

On November 11, 2024,